抗凝房颤患者下消化道出血与结直肠癌风险
基于丹麦行政登记数据,纳入125 418例启动口服抗凝治疗的房颤患者,评估下消化道出血后结直肠癌的绝对风险。随访至多3年,2576例发生下消化道出血,其中140例在出血后1年内确诊结直肠癌。各年龄组下消化道出血后1年结直肠癌绝对风险为3.7%至8.1%,风险比最高达24.2。下消化道出血不应视为抗凝治疗的良性后果,应始终排查潜在恶性肿瘤。
要点
- 抗凝房颤患者下消化道出血后1年内结直肠癌绝对风险为3.7%至8.1%。
- 与无下消化道出血者相比,各年龄组结直肠癌风险比最高达24.2。
- 下消化道出血不应视为抗凝治疗的良性后果,应排查潜在恶性肿瘤。
核心结论
- 在抗凝治疗的房颤患者中,下消化道出血提示较高的结直肠癌绝对风险,不应视为抗凝治疗的良性后果,应始终排查潜在恶性病因。
研究设计与样本
- 基于丹麦行政登记数据,纳入125 418例启动口服抗凝治疗的房颤患者,采用非参数估计与半参数绝对风险回归评估下消化道出血后结直肠癌的绝对风险。
主要发现
- 随访至多3年,2576例患者发生下消化道出血,其中140例在出血后1年内确诊结直肠癌。
- 各年龄组下消化道出血后1年结直肠癌绝对风险为3.7%(95%CI 2.2-6.2)至8.1%(95%CI 6.1-10.6),分别对应≤65岁和76-80岁年龄组。
- 与无下消化道出血者相比,各年龄组结直肠癌风险比升高,≤65岁组风险比为24.2(95%CI 14.5-40.4),>85岁组为12.3(95%CI 7.9-19.0)。
临床怎么用
- 抗凝房颤患者发生下消化道出血时,不应仅归因于抗凝治疗,应评估是否存在潜在结直肠癌。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Gastrointestinal bleeding (GI-bleeding) is frequent in patients with atrial fibrillation (AF) treated with oral anticoagulation (OAC) therapy. We sought to investigate to what extent lower GI-bleeding represents the unmasking of an occult colorectal cancer. METHODS AND RESULTS: A total of 125 418 Danish AF patients initiating OAC therapy were identified using Danish administrative registers. Non-parametric estimation and semi-parametric absolute risk regression were used to estimate the absolute risks of colorectal cancer in patients with and without lower GI-bleeding. During a maximum of 3 years of follow-up, we identified 2576 patients with lower GI-bleeding of whom 140 patients were subsequently diagnosed with colorectal cancer within the first year of lower GI-bleeding. In all age groups, we observed high risks of colorectal cancer after lower GI-bleeding. The absolute 1-year risk ranged from 3.7% [95% confidence interval (CI) 2.2-6.2] to 8.1% (95% CI 6.1-10.6) in the age groups ≤65 and 76-80 years of age, respectively. When comparing patients with and without lower GI-bleeding, we found increased risk ratios of colorectal cancer across all age groups with a risk ratio of 24.2 (95% CI 14.5-40.4) and 12.3 (95% CI 7.9-19.0) for the youngest and oldest age group of ≤65 and >85 years, respectively. CONCLUSION: In anticoagulated AF patients, lower GI-bleeding conferred high absolute risks of incident colorectal cancer. Lower GI-bleeding should not be dismissed as a benign consequence of OAC therapy but always examined for a potential underlying malignant cause.
引用
- Rasmussen PV, Dalgaard F, Gislason GH, et al. Gastrointestinal bleeding and the risk of colorectal cancer in anticoagulated patients with atrial fibrillation. Eur Heart J. 2022. PMID: 32030399. doi:10.1093/eurheartj/ehz964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。